Pharma Client Accelerates Market Access by 30% with Real-World Evidence Analytics

A multi-billion-dollar drug launch risks stalling when payers and regulators demand proof of value beyond traditional clinical trial data. For a leading pharmaceutical company, this exact scenario threatened to derail revenue forecasts for their flagship product, with market access negotiations hitting a wall due to a perceived lack of long-term efficacy data. The gap between controlled trial results and actual patient outcomes created a significant evidence challenge. This is where a robust real-world evidence strategy becomes critical. By systematically analyzing disparate sources of real-world data (RWD) such as electronic health records, insurance claims, and patient registries, companies can construct a compelling narrative about a drug's performance, safety, and economic value in everyday clinical practice. This case study details how Quantzig’s analytics framework transformed the client's scattered real-world data into a powerful strategic asset, directly leading to a 30% acceleration in reimbursement decisions and securing critical formulary access.

Key Highlights

• Client's Strategic Imperative

  A mid-sized pharmaceutical firm needed to substantiate the value proposition of a newly launched specialty drug to accelerate market access. Their primary objective was to move beyond the limitations of their Phase III clinical trial data and generate robust real-world evidence that demonstrated the drug's effectiveness and economic benefits in a diverse patient population. They aimed to leverage this evidence to successfully negotiate with national payers and health technology assessment (HTA) bodies, who were increasingly demanding proof of performance in routine clinical settings to justify premium pricing and formulary inclusion. The goal was to build a sustainable capability for evidence generation.

• The Evidence Generation Gridlock

  The core challenge was a fragmented and inaccessible data landscape. The client possessed vast amounts of raw real-world data from sources like EHRs, claims databases, and patient support programs, but it was siloed, unstructured, and inconsistent. They lacked the internal expertise and analytical infrastructure to integrate these disparate datasets and perform the complex analyses required to generate credible real-world evidence. This inability to produce timely, methodologically sound studies on patient outcomes and comparative effectiveness created a significant bottleneck, delaying crucial reimbursement negotiations and hindering physician adoption due to a lack of supporting real-world proof.

• A Unified RWE Analytics Solution

  Quantzig designed and deployed a comprehensive real-world evidence analytics solution. The engagement began by creating a unified data model to ingest, clean, and harmonize the client's diverse real-world data sources. We then applied a suite of advanced analytical techniques, including propensity score matching to create synthetic control arms and longitudinal patient journey mapping to analyze treatment patterns over time. This framework enabled the generation of robust health economics and outcomes research (HEOR) insights. The solution provided a repeatable and scalable process for turning raw data into compelling evidence dossiers for payers.

• Measurable Commercial Impact

  The solution unlocked significant and measurable commercial success. The compelling real-world evidence dossier directly led to a 30% reduction in the average time for payer reimbursement decisions. This acceleration was critical in a competitive market. Furthermore, the evidence helped secure a 17-percentage-point increase in formulary acceptance among key national payers, dramatically expanding market access. The analytics platform reduced the time required to prepare an evidence submission from over three months to just three weeks, enabling a more agile and responsive market access strategy.

Problem Statement

A leading pharmaceutical company faced a critical business challenge: the market uptake of its newly launched, high-potential specialty drug was significantly underperforming against forecasts. While the drug had demonstrated safety and efficacy in rigorous Phase III clinical trials, payers and healthcare providers were hesitant to grant broad access and adoption without stronger proof of its value in real-world settings. The client was struggling to answer crucial questions about long-term patient outcomes, comparative effectiveness against existing treatments, and the drug's overall economic impact. The central problem was an organizational inability to translate a wealth of available but chaotic real-world data into cohesive, credible, and compelling real-world evidence. Their data ecosystem was a patchwork of siloed systems containing electronic health records, claims data, and pharmacy dispensing information. This fragmentation, combined with a lack of specialized analytical tools and biostatistical expertise, created a chasm between data acquisition and insight generation. As a result, the market access team was ill-equipped for negotiations, and the company was losing ground to competitors, jeopardizing hundreds of millions in potential revenue.

• Fragmented Data Ecosystem : The client's data was spread across numerous, disconnected sources, including electronic health records (EHRs), insurance claims databases, and patient registries. Each source used different coding standards, formats, and definitions, with significant issues of missing or incomplete data. This lack of a unified data foundation made it impossible to perform integrated analysis, track patient journeys across care settings, or generate the reliable real-world evidence needed to satisfy payer requirements. The data was an untapped, unusable asset.
• Inadequate Analytical Infrastructure : The company’s internal business intelligence teams were skilled in sales reporting but lacked the specialized expertise for advanced real-world evidence analytics. They could not execute complex statistical methods such as propensity score matching, survival analysis, or the creation of synthetic control arms from observational data. This methodological gap meant they were unable to produce the level of evidence needed to demonstrate comparative effectiveness, a key demand from sophisticated payers and HTA bodies, leaving their value arguments unsubstantiated.
• Intensifying Payer Scrutiny : Payers and regulatory bodies were increasingly demanding robust real-world evidence to validate the value propositions of new, high-cost therapies. The client's inability to provide methodologically sound RWE studies put them at a severe disadvantage during market access negotiations. Competitors who could present strong real-world data were securing more favorable formulary placement and reimbursement terms. The client's lack of evidence was directly translating into restricted patient access and lost revenue opportunities.
• Reactive and Slow Insight Generation : The existing process for analyzing any post-market data was manual, slow, and reactive. It took months for the client to respond to a single query from a payer. By the time an analysis was complete, the market dynamics had often shifted, rendering the insights obsolete. This significant time lag prevented the commercial and medical teams from proactively identifying opportunities, addressing physician concerns, or detecting important safety signals in a timely manner, forcing them into a perpetually defensive posture.

The breaking point arrived during a quarterly business review when the executive board was confronted with a stark reality. A major national payer, representing millions of potential patients, had formally deferred a formulary decision for their flagship drug for the second consecutive quarter. The payer's feedback was brutally direct: 'insufficient evidence of superior long-term outcomes and budget impact compared to existing alternatives.' This one decision single-handedly jeopardized the entire fiscal year's revenue forecast and sent a shockwave through the organization. The long-held belief that a successful Phase III trial was the finish line for market access was shattered. The status quo—relying on a small, internal team to manually sift through fragmented data—was no longer just inefficient; it was a direct threat to the company's commercial viability. It became painfully clear that they needed a new strategy and a partner who could transform their messy, dormant real-world data into a decisive strategic weapon.

Objectives

• Unify RWD Sources : The primary objective was to architect and build a unified data asset by integrating disparate real-world data sources, including claims, EHR, and patient-reported outcomes. Achieving this would create a longitudinal, 360-degree view of the patient journey. This single source of truth would eliminate data silos and serve as the foundational layer for all subsequent analysis, dramatically enhancing the analytics team's efficiency and the reliability of their findings.
• Develop Advanced Analytics Models : A key goal was to develop and validate a suite of advanced statistical models to derive meaningful insights from the unified data. This included building algorithms to create synthetic control arms for comparative effectiveness research, as well as predictive models to identify patient subgroups most likely to benefit from the therapy. This would elevate the client’s analytics capability from descriptive reporting to predictive and prescriptive evidence generation, providing a far more powerful negotiating tool.
• Accelerate Evidence Generation : To drastically reduce the evidence generation lifecycle from months to a matter of weeks. This objective focused on creating a streamlined, semi-automated analytics workflow for key tasks like post-market surveillance and HEOR analysis. By improving operational efficiency, the client could respond to ad-hoc requests from payers and regulators with unprecedented speed, turning their evidence generation function into a competitive advantage rather than a bottleneck.
• Support Market Access Strategy : The ultimate business objective was to generate a portfolio of compelling real-world evidence packages specifically designed to support market access negotiations. This involved translating complex analytical findings into clear, concise, and visually impactful value stories that directly addressed the evidence gaps previously identified by payers. Achieving this would empower the market access team to lead negotiations from a position of strength, backed by robust, data-driven proof.

Solution Implemented

Quantzig delivered a comprehensive, multi-phase real-world evidence analytics solution designed to transform the client's data into a strategic asset. Our approach began with establishing a data-agnostic ingestion and harmonization framework, which consolidated and standardized various RWD types into a common data model. Following data preparation, we deployed advanced statistical modeling and machine learning techniques to analyze patient cohorts, identify complex treatment patterns, and quantify both clinical and economic outcomes. The solution culminated in the delivery of a series of interactive dashboards and a detailed evidence dossier, providing the client's commercial and medical affairs teams with on-demand, actionable insights for their stakeholder engagements.

• Data Harmonization Engine : Implemented a common data model (OMOP) to standardize and integrate disparate EHR, claims, and registry data.
• Synthetic Control Arm (SCA) Generation : Used propensity score matching on observational data to simulate a comparator group for robust effectiveness analysis.
• Longitudinal Patient Journey Mapping : Analyzed patient pathways over time to understand treatment sequencing, adherence, and real-world patient outcomes.
• HEOR Modeling Platform : Developed dynamic health economics models to quantify the drug's cost-effectiveness and budget impact for payer submissions.
• Evidence Dissemination Dashboard : Built an interactive Power BI dashboard for teams to explore RWE insights and tailor data for specific negotiations.

Technologies Used

• Python & R for Statistical Modeling : We leveraged Python (using libraries like Pandas and Scikit-learn) and R for the core data manipulation and advanced statistical modeling. R was particularly critical for implementing sophisticated epidemiological methods required for credible real-world evidence, such as survival analysis (Kaplan-Meier curves) and propensity score matching algorithms. This open-source stack ensured the analytical methodology was transparent, reproducible, and aligned with academic and regulatory standards, which was essential for building trust with external stakeholders like HTA bodies.
• Databricks for Big Data Processing : The immense volume and complexity of patient-level real-world data, especially from unstructured EHR notes and large claims databases, necessitated a powerful and scalable processing engine. We utilized the Databricks Unified Analytics Platform, running on a cloud environment, to execute large-scale data transformations and model training using Apache Spark. This distributed computing framework reduced data processing times from days to hours, enabling our data scientists to iterate on analytical models much faster and accelerating the overall evidence generation timeline.
• OMOP Common Data Model : To overcome the critical challenge of fragmented, siloed data, we implemented the Observational Medical Outcomes Partnership (OMOP) Common Data Model. All incoming source data from EHRs, claims, and other systems were systematically mapped to this standardized structure and vocabulary. This created a single, analysis-ready, and cohesive dataset. Adopting the OMOP CDM was a crucial strategic decision that not only enabled this project but also positioned the client for future network studies and easier integration of new real-world data sources.
• Power BI for Insight Visualization : The final insights were delivered not as a static report but through a suite of interactive Power BI dashboards. This technology was chosen to empower non-technical users in the commercial, medical affairs, and market access teams. They could independently explore the real-world evidence, filter by patient demographics or regions, drill down into specific outcome metrics, and export customized views for their presentations. This transformed the solution from a one-off analysis into a dynamic, self-service strategic asset for ongoing decision-making.

Request a demo

Results and Impact

Quantzig's real-world evidence analytics solution delivered transformative results, directly resolving the client's critical market access gridlock and establishing a new internal capability. By converting their latent, fragmented real-world data into a strategic, evidence-generating asset, we empowered the client to articulate a powerful and quantifiable value story. The insights produced were instrumental in re-engaging key payers from a position of strength, leading to tangible commercial victories that had been unattainable just months prior. More than a one-time project, our solution provided a sustainable and scalable platform for ongoing post-market surveillance and evidence generation. This fundamentally shifted the client's posture from being reactive to payer demands to proactively shaping the market's perception of their product's real-world performance, definitively resolving their core problem of stalled adoption and unlocking revenue potential.

Qualitative Impact

• From Reactive Reporting to Proactive Insight Generation : Operationally, the daily work of the client's HEOR and medical affairs teams was transformed. Previously, they spent the majority of their time on tedious manual data extraction and responding to ad-hoc report requests. With the new automated analytics platform, their focus shifted entirely to high-value strategic activities. They now spend their days exploring hypotheses in the interactive dashboard, proactively identifying patient sub-populations where the drug shows exceptional benefit, and preparing evidence packages for payer reviews months in advance. Team meetings evolved from troubleshooting data issues to debating strategic interpretations of the real-world evidence, effectively turning a support function into a strategic insights engine.
• Enabling Value-Based Contracting and Label Expansion : Strategically, the ability to generate robust real-world evidence on demand unlocked major business decisions that were previously out of reach. Armed with credible data on long-term outcomes, the executive team initiated discussions with several large payers to pilot value-based contracts, where reimbursement is tied to the drug's real-world performance. Furthermore, the granular RWE on off-label usage patterns provided the foundational evidence needed to justify a supplemental new drug application (sNDA) to formally expand the drug's approved indications. These strategic initiatives, directly enabled by the analytics solution, are projected to create significant new revenue streams.
• Fostering a Unified, Data-Driven Culture : Perhaps the most profound impact was the cultural shift in how the organization valued and used data. Initially, deep skepticism existed between the commercial teams, who trusted sales numbers, and the medical teams, who trusted clinical trial data. The new RWE platform, with its transparent methodology and clear visualizations, became a unifying 'single source of truth' that both sides trusted. Brand managers, medical science liaisons, and market access teams began collaborating within the platform, breaking down functional silos. This fostered a shared understanding and a genuine culture of data-driven decision-making, aligning the entire organization around the common language of real-world evidence.
• Positioning for Future Leadership in RWE : This engagement did more than solve an immediate problem; it provided the client with a foundational capability to lead in an increasingly data-driven healthcare landscape. With the scalable real-world evidence platform in place, they are no longer just a drug manufacturer but an information-rich life sciences organization. They are now actively exploring the integration of new data sources like genomics and patient wearables to further enrich their analyses. The next strategic horizon involves using the platform's predictive analytics to identify at-risk patients and inform personalized medicine strategies, securing their competitive advantage for the next decade.

How Quantzig Can Help

The success of this engagement was the direct result of Quantzig's deep-seated expertise in the pharmaceutical industry's unique data, regulatory, and commercial challenges. For over 18 years, we have been at the forefront of life sciences analytics, developing proprietary frameworks that transform disparate real-world data into compelling, regulatory-grade real-world evidence. Our cross-functional teams—comprising data scientists, biostatisticians, and pharma domain experts—possess a nuanced understanding of health economics and outcomes research (HEOR), comparative effectiveness, and post-market surveillance. This specialized mastery allows us to navigate common pitfalls in RWE studies, such as selection bias and confounding variables, by implementing sophisticated techniques like propensity score matching and synthetic control arm generation with scientific rigor. The client's ability to accelerate reimbursement by 30% is a direct testament to our approach, which prioritizes commercially relevant and methodologically sound analytics. This case study exemplifies Quantzig's exceptional capability to dissect complex business problems at the intersection of data, medicine, and market access. Our extensive background in handling sensitive patient-level data and navigating the complex demands of payers ensures that our solutions are not only analytically robust but also strategically potent, providing clients with a sustainable competitive advantage built on a foundation of trusted real-world evidence.

Quantzig's Expertise in Real-World Evidence Analytics

• Deep Pharma Domain Knowledge : Our team includes biostatisticians and HEOR experts who understand the specific evidence requirements of payers and regulators, ensuring our analytical outputs directly address critical market access and clinical questions.
• Advanced RWE Methodologies : We specialize in advanced techniques like synthetic control arm creation and longitudinal patient journey analysis, turning observational data into robust evidence that withstands scientific and regulatory scrutiny.
• Scalable Data Integration Frameworks : Our experience with diverse health data formats (EHR, claims) and models like OMOP allows us to rapidly build unified data assets, accelerating the entire real-world evidence generation lifecycle for our clients.